SB 568849
Latest Information Update: 30 Nov 2004
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Class Anxiolytics; Obesity therapies
- Mechanism of Action Melanin-concentrating hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Obesity
Most Recent Events
- 30 Nov 2004 Discontinued - Preclinical for Anxiety disorders in United Kingdom (unspecified route)
- 30 Nov 2004 Discontinued - Preclinical for Obesity in United Kingdom (unspecified route)
- 23 Sep 2002 Preclinical trials in Anxiety disorders in United Kingdom (unspecified route)